O sistema renina-angiotensina e o estresse oxidativo têm participação importante na fisiopatologia das complicações crônicas do diabetes. No presente estudo, foram avaliados 103 pacientes com diabetes tipo 1 (DM1) com idade de 28,810,6 anos e duração de doença de 13,18,5 anos e 158 controles não diabéticos quanto à presença dos polimorfismos I/D da ECA e C242T do p22phox, componente essencial para a ativação da NADPH oxidase. Esta análise foi realizada por reação de polimerase em cadeia para ambos os polimorfismos, seguida de restrição enzimática para avaliação do polimorfismo C242T p22phox. Ambas as distribuições genotípicas obedeciam ao princípio do equilíbrio de Hardy-Weinberg. Os pacientes diabéticos foram submetidos a avaliação clínica e laboratorial quanto à presença de fatores associados ao risco de complicações (história de tabagismo e antecedentes familiares de diabetes tipo 2, dose diária de insulina, níveis pressóricos, índice de massa corporal, relação cintura-quadril, excreção urinária de albumina, taxa de filtração glomerular, perfil lipídico, controle glicêmico, níveis de proteína C-reativa) e rastreados quanto à presença de nefropatia diabética, considerada presença de micro ou macroalbuminúria; retinopatia diabética não proliferativa ou proliferativa e hipertensão arterial. Não houve diferença significativa entre a presença dos alelos D e I da ECA ou C e T do p22phox entre diabéticos e controles. Os polimorfismos avaliados não apresentaram associação com a presença de nefropatia, retinopatia ou hipertensão arterial. Pacientes portadores do alelo D apresentaram maiores níveis de pressão arterial diastólica (72,2 12,3 vs 65,4 11,6 mmHg , p=0,047) e proteína C-reativa comparados aos portadores do genótipo II [0,18 (0,04-0,38) vs 0,09 (0,04-0,16) mg/dl, p=0,05] , porém ambas as análises perderam significância estatística após correção para duração do diabetes. A combinação dos polimorfismos não esteve associada à presença de complicações microvasculares ou hipertensão arterial. Concluímos que, na população de diabéticos tipo 1 estudada, a frequência dos polimorfismos I/D da ECA e C242T do p22phox , isoladamente ou em combinação, não apresentou diferença em pacientes com ou sem complicações microvasculares precoces ou hipertensão arterial. Os níveis dos diferentes marcadores de risco cardiovascular também não apresentaram diferença nos pacientes com os polimorfismos acima descritos. Entretanto, estudos prospectivos poderão determinar a possível interação entre estes polimorfismos e a duração do diabetes na expressão clínica das complicações crônicas da doença. / The renin-angiotensin system and the oxidative stress play an important role in the pathogenesis of the diabetic complications.In the present study 103 patients with type 1 diabetes (T1DM) aged 28.8 10.6 years and with a disease duration of 13.1 8.5 years and 158 non-diabetic controls were evaluated for the presence of the I / D polymorphism of the angiotensin converting enzyme (ACE) and the C242T polymorphism of the p22phox, an essential component for NADPH oxidase activation. The analysis was performed using polymerase chain reaction for both polymorphisms, followed by enzymatic restriction for C242T p22phox polymorphism. Genotypic distributions of both polymorphisms were in Hardy-Weinberg equilibrium. Diabetic patients underwent clinical and laboratory evaluation for the presence of risk factors associated with complications of diabetes (smoking and family history of type 2 diabetes, daily insulin dose, blood pressure, body mass index, waist hip ratio, urinary albumin excretion, glomerular filtration rate, lipid profile, glycemic control, C-reactive protein levels) and screened for the presence of diabetic nephropathy, considered as the presence of micro or macroalbuminuria, diabetic retinopathy and hypertension. There was no significant difference between the presence of ACE D or I allele and p22phox C or T allele between diabetic patients and controls. The evaluated polymorphisms were not associated with the presence of nephropathy, retinopathy or hypertension. Patients with the D allele showed higher levels of diastolic blood pressure (72.2 12.3 vs 65.4 11.6 mmHg, p = 0.047) and C-reactive protein compared with those carrying the II genotype [0.18 (0.04-0.38) vs 0.09 (0.04-0.16) mg/dl, p = 0.05], but both analysis lost statistical significance after correction for duration of diabetes. The combination of both polymorphisms was not associated with microvascular complications or hypertension. We conclude that in the studied population of type 1 diabetic patients, the frequency of ACE I / D and C242T of p22phox polymorphisms, alone or in combination, was not different in patients with or without early microvascular complications or hypertension. Also, the levels of different markers of cardiovascular risk did not differ for patients with the polymorphisms described above. However, prospective studies may determine the possible interaction between these polymorphisms and duration of diabetes in the clinical expression of chronic complications of diabetes.

Made available in DSpace on 2016-06-02T20:18:17Z (GMT). No. of bitstreams: 1 4192.pdf: 6083601 bytes, checksum: a411c24424aa71f8ff5f0404ef48215b (MD5) Previous issue date: 2012-02-16 / Universidade Federal de Sao Carlos / The multifactorial nature of coronary artery disease (CAD) includes complications related to angina and acute myocardial infarction (AMI) and disorders involving sympathetic and parasympathetic cardiac autonomic modulation. The objective of this study was to evaluate the autonomic modulation of heart rate (HR) by linear and non-linear methods in healthy men and in patients with AMI and different percentages of coronary stenosis, as well as its relation with CAD risk factors. In order to evaluate heart rate variability (HRV), the HR and the RR intervals were recorded for 15 min in the supine position. Based on the results of this study, three manuscripts were written: The first manuscript presents the results of 10 men with AMI (57±9 years old) (2nd and 7th day after coronary event) and 11 healthy men (53±4 years old). The HRV analysis was carried out using linear methods in the time domain (TD=RMSSD and SDNN) and frequency domain (FD= low frequency (LF) and high frequency (HF) in normalized units (nu) and LF/HF) and using the non-linear methods approximate entropy (ApEn). A significant relationship between the linear and non-linear methods and the RMSSD, SDNN, LFun, HFun and LF/HF and ApEn indexes was observed. The linear and non-linear HRV indexes from the healthy group were higher than those of the AMI group on the 2nd and 7th days, which suggests that the analysis of HRV with linear methods in the TD and FD and the use of ApEn for linear analysis are in agreement, both for healthy subjects and patients after AMI. The second manuscript presents the results of 52 men (54±5 years old) divided into two groups with coronary obstruction CAD+ &#8805; 50% (n=18) and CAD- < 50% (n=17) and one control group (n=17). HRV analysis was carried out with Shannon entropy (SE) and symbolic analysis (0V and 2ULV). The patients with DAC+ presented lower SE (complexity), 2ULV (vagal predominance) and higher 0V (sympathetic predominance) than the DAC- and control groups, which indicates that cardiac autonomic disorder is related to the degree of coronary occlusion and to cardiac impairment. The third manuscript presents the results for risk factors, ACE I/D polymorphism and the indexes in the TD and FD of 151 patients with CAD (56±8 years old, DD=54, DI=70 and II=27). The results show that there was no relation between the ACE I/D polymorphism and HR, BP or HRV. However, the highest indexes of the HRV, which reflect vagal autonomic modulation, are related to a lower percentage of stenosis and the use of ACE inhibitors. / A doença arterial coronariana (DAC) é de natureza multifatorial sendo que as principais complicações estão relacionadas à angina e infarto agudo do miocárdio (IAM), apresentando disfunção da modulação autonômica cardíaca simpática e parassimpática. Assim, o objetivo foi avaliar a modulação autonômica da frequência cardíaca (FC), a partir de métodos lineares e não lineares, de homens saudáveis, de pacientes com IAM e com diferentes percentuais de estenose coronariana e sua relação com os fatores de risco para a DAC. Para a análise da variabilidade da FC (VFC) foi realizada a captação dos intervalos RR e da FC, durante 15 min na posição supina. A partir dos resultados do estudo foram elaborados três manuscritos. Primeiro manuscrito: Foram apresentados os resultados de 10 homens com IAM (57±9 anos) (avaliados no 2º e 7 º dia após evento coronariano) e 11 homens saudáveis (53±4 anos). A análise da VFC foi realizada utilizando-se dos métodos lineares no domínio do tempo (DT=RMSSD e RMSM) e da frequência (DF=baixa frequência (BF) e alta frequência (AF) em unidades normalizadas (un) e BF/AF) e pelo método não linear de entropia aproximada (EnAp). As análises da relação entre os métodos lineares e o não linear (índices RMSSD, RMSM, BFun, AFun e BF/AF com a EnAp) foi significativa. Os índices lineares e não linear da VFC do grupo saudável foram maiores em relação ao grupo IAM no 2º e no 7º dia. Os resultados mostram que os métodos lineares no DT e no DF e o não linear , são concordantes, para análise da VFC, tanto para voluntários saudáveis como para pacientes após o IAM. Segundo manuscrito: Foram apresentados os resultados de 52 homens (54±5 anos) divididos em três grupos, sendo dois grupos com obstrução coronariana DAC+ (&#8805; 50%; n=18) e DAC- (< 50%; n=17) e um grupo controle (n=17). A análise da VFC foi pela entropia de Shannon (ES) e análise simbólica (0V e 2ULV). Os pacientes com DAC+ apresentam menor ES (complexidade) e 2ULV (predominância vagal) e maior 0V (predominância simpática) quando comparado aos grupos DAC- e controle, o que indica que a disfunção autonômica cardíaca está relacionada ao grau de oclusão coronariana. Terceiro manuscrito: Foram apresentados os resultados da possível relação existente entre dos fatores de risco, do polimorfismo I/D do gene da ECA com os índices no DT e no DF de 151 pacientes com DAC (56±8 anos, DD=54, DI=70 e II=27). Os resultados mostram que não há relação entre o polimorfismo I/D do gene da ECA com a FC, PA e VFC. Já os maiores índices da VFC que refletem a modulação autonômica vagal estão relacionados ao menor percentual de estenose e ao uso de inibidores da ECA.

O sistema renina-angiotensina e o estresse oxidativo têm participação importante na fisiopatologia das complicações crônicas do diabetes. No presente estudo, foram avaliados 103 pacientes com diabetes tipo 1 (DM1) com idade de 28,810,6 anos e duração de doença de 13,18,5 anos e 158 controles não diabéticos quanto à presença dos polimorfismos I/D da ECA e C242T do p22phox, componente essencial para a ativação da NADPH oxidase. Esta análise foi realizada por reação de polimerase em cadeia para ambos os polimorfismos, seguida de restrição enzimática para avaliação do polimorfismo C242T p22phox. Ambas as distribuições genotípicas obedeciam ao princípio do equilíbrio de Hardy-Weinberg. Os pacientes diabéticos foram submetidos a avaliação clínica e laboratorial quanto à presença de fatores associados ao risco de complicações (história de tabagismo e antecedentes familiares de diabetes tipo 2, dose diária de insulina, níveis pressóricos, índice de massa corporal, relação cintura-quadril, excreção urinária de albumina, taxa de filtração glomerular, perfil lipídico, controle glicêmico, níveis de proteína C-reativa) e rastreados quanto à presença de nefropatia diabética, considerada presença de micro ou macroalbuminúria; retinopatia diabética não proliferativa ou proliferativa e hipertensão arterial. Não houve diferença significativa entre a presença dos alelos D e I da ECA ou C e T do p22phox entre diabéticos e controles. Os polimorfismos avaliados não apresentaram associação com a presença de nefropatia, retinopatia ou hipertensão arterial. Pacientes portadores do alelo D apresentaram maiores níveis de pressão arterial diastólica (72,2 12,3 vs 65,4 11,6 mmHg , p=0,047) e proteína C-reativa comparados aos portadores do genótipo II [0,18 (0,04-0,38) vs 0,09 (0,04-0,16) mg/dl, p=0,05] , porém ambas as análises perderam significância estatística após correção para duração do diabetes. A combinação dos polimorfismos não esteve associada à presença de complicações microvasculares ou hipertensão arterial. Concluímos que, na população de diabéticos tipo 1 estudada, a frequência dos polimorfismos I/D da ECA e C242T do p22phox , isoladamente ou em combinação, não apresentou diferença em pacientes com ou sem complicações microvasculares precoces ou hipertensão arterial. Os níveis dos diferentes marcadores de risco cardiovascular também não apresentaram diferença nos pacientes com os polimorfismos acima descritos. Entretanto, estudos prospectivos poderão determinar a possível interação entre estes polimorfismos e a duração do diabetes na expressão clínica das complicações crônicas da doença. / The renin-angiotensin system and the oxidative stress play an important role in the pathogenesis of the diabetic complications.In the present study 103 patients with type 1 diabetes (T1DM) aged 28.8 10.6 years and with a disease duration of 13.1 8.5 years and 158 non-diabetic controls were evaluated for the presence of the I / D polymorphism of the angiotensin converting enzyme (ACE) and the C242T polymorphism of the p22phox, an essential component for NADPH oxidase activation. The analysis was performed using polymerase chain reaction for both polymorphisms, followed by enzymatic restriction for C242T p22phox polymorphism. Genotypic distributions of both polymorphisms were in Hardy-Weinberg equilibrium. Diabetic patients underwent clinical and laboratory evaluation for the presence of risk factors associated with complications of diabetes (smoking and family history of type 2 diabetes, daily insulin dose, blood pressure, body mass index, waist hip ratio, urinary albumin excretion, glomerular filtration rate, lipid profile, glycemic control, C-reactive protein levels) and screened for the presence of diabetic nephropathy, considered as the presence of micro or macroalbuminuria, diabetic retinopathy and hypertension. There was no significant difference between the presence of ACE D or I allele and p22phox C or T allele between diabetic patients and controls. The evaluated polymorphisms were not associated with the presence of nephropathy, retinopathy or hypertension. Patients with the D allele showed higher levels of diastolic blood pressure (72.2 12.3 vs 65.4 11.6 mmHg, p = 0.047) and C-reactive protein compared with those carrying the II genotype [0.18 (0.04-0.38) vs 0.09 (0.04-0.16) mg/dl, p = 0.05], but both analysis lost statistical significance after correction for duration of diabetes. The combination of both polymorphisms was not associated with microvascular complications or hypertension. We conclude that in the studied population of type 1 diabetic patients, the frequency of ACE I / D and C242T of p22phox polymorphisms, alone or in combination, was not different in patients with or without early microvascular complications or hypertension. Also, the levels of different markers of cardiovascular risk did not differ for patients with the polymorphisms described above. However, prospective studies may determine the possible interaction between these polymorphisms and duration of diabetes in the clinical expression of chronic complications of diabetes.

Organic nitrates, such as nitroglycerine (NTG), are widely used for their potent vasodilator capacity in the management of coronary artery disease and heart failure. Unfortunately, their beneficial effect is rapidly lost due to the development of nitrate tolerance, which is translated by an impaired vasorelaxation to NTG and an increased oxidative stress production. Although the mechanisms of the development of nitrate tolerance are still not fully elucidated, much interest has been focused in treating nitrate-receiving patients together with other drugs in order to overcome the development of nitrate tolerance. The Nitric Oxide generating enzyme, eNOS, and the superoxide anion generating enzyme, NAD(P)H oxidase, have been suggested to play a role in the development of nitrate tolerance. The aim of this study was to analyse the underlying mechanism by which ramipril, an ACE inhibitor and rosuvastatin, a new molecule of the statin class, are able to protect against the development of nitrate tolerance in the aortas isolated from rats, wild-type (wt) and eNOS-/- mice. <p>These results show that ramipril as well as rosuvastatin are able to protect against the development of nitrate tolerance in the wt and eNOS-/- mice aortas suggesting that eNOS is not necessary for their protective effect. The aortas from nitrate tolerant rats and mice showed a significant increase in the NAD(P)H oxidase activation compared to the aortas from the control and from the co-treated ramipril+NTG or rosuvastatin+NTG animals. In line with these findings were the results obtained by RT-PCR analysis: the mRNA expression of the different subunits of the NAD(P)H oxidase, such as gp91phox, p22phox, were significantly decreased after rosuvastatin or ramipril treatment in wt and eNOS-/- mice aortas. Apocynin, the NAD(P)H oxidase inhibitor was also able to inhibit the development of nitrate tolerance in the rat and mouse aortas. <p>In conclusion, these results suggest that rosuvastatin and ramipril are able to protect against the development of nitrate tolerance by counteracting the nitrate-induced oxidative stress. The mechanism of protection involves a direct interaction with the NAD(P)H oxidase pathway and seems to be completely independent of the eNOS pathway. <p> / Doctorat en sciences pharmaceutiques / info:eu-repo/semantics/nonPublished

Doctor Pharmaceuticae - DPharm / Tulbaghia violacea Harv. (Alliaceae) is a small bulbous herb which belongs to the family, Alliaceae, most commonly associated with onions and garlic. In South Africa (SA), this herb has been traditionally used in the treatment of various ailments, including fever, colds, asthma, paralysis, hypertension (HTN) and stomach problems. The aim of this study was to evaluate the effect of methanol leaf extracts (MLE) of T. violacea on the blood pressure (BP) and heart rate (HR) in anaesthetized male spontaneously hypertensive rats and to find out the mechanism(s) by which it acts. The MLE of T. violacea (5 - 150 mg/kg), angiotensin I (ang I, 3.1 - 100 mg/kg), captopril (10 mg/kg), angiotensin II (ang II, 3.1 - 50 g/kg), losartan (30 mg/kg), phenylephrine (0.01 ; 0.16 mg/kg), prazosin (1 mg/kg), dobutamine (0.2 ; 10.0mg/kg), propranolol (0.1 - 12.8 mg/kg), muscarine (0.16 -10 mg/kg), and atropine (0.02 - 20.48 mg/kg) were administered intravenously into male spontaneously hypertensive rats (SHR) weighing between 300 g and 350 g and aged less than 5; months. The MLE of T. violacea and/or the standard drugs were infused alone, simultaneously, or separately into each animal. The BP and HR were measured via a pressure transducer connecting the femoral artery and the Powerlab. The vehicle (0.2 mls of a mixture of dimethylsulfoxide and normal saline), T. violacea (60 mg/kg) and captopril (10 mg/kg) were injected intraperitoneally into some SHR for 21 days to investigate the chronic effect of these agents on plasma levels of aldosterone. The mean change, the mean of the individual percentage changes and the percentage difference (in mean) observed with each intervention was calculated and statistically analyzed using the Student t test for significant difference (p < 0.05). The Microsoft Excel software was used for statistical analysis. T. violacea significantly (p < 0.05) reduced the systolic, diastolic, and mean arterial BP; and HR dose-dependently. In a dose-dependent manner, ang I, ang II, phenylephrine significantly (p < 0.05) increased the BP, while propranolol, muscarine and atropine reduced the BP. The increases in BP due to dobutamine were not dose-dependent. In a dose dependent manner, phenylephrine and propranolol reduced the HR, while dobutamine increased the HR. The effect of ang I, ang II, muscarine and atropine on HR were not dose-dependent; with both increases as well as decreases observed with ang I, and II and atropine, while decreases were seen with muscarine. Captopril produced significant (p < 0.05) reduction in BP which were not associated with any change in HR. The co-infusion of ang I with the MLE produced significant (p < 0.05) reduction in BP, which were not associated with significant changes in HR. The co-infusion of ang II with the MLE did not produce any significant changes in BP or HR when compared to the infusion of the standard drug alone. The co-infusion of phenylephrine with the MLE did not produce any significant change in BP or HR when compared to the values obtained with the infusion of the standard drug alone, in both the absence and presence of prazosin. The co-infusion of dobutamine with T. violacea produced siginificant (p < 0.05) increases in DBP which were associated with significant (p < 0.05) reductions in HR, when compared to the values obtained with the infusion of the standard drug alone. Theco-infusion of atropine with the MLE did not produce any significant change in BP or HR when compared to the values obtained with the infusion of atropine alone. However, the infusion of T. violacea, 20 minutes after pre-treating animals with atropine (5.12 mg/kg) lead to dose dependent significant (p< 0.05) increases in BP, which were associated with dose-dependent increases in HR. The chronic treatment of animals with T. violacea or captropril produced (a) signicant (p < 0.05) reductions in the plasma levels of aldosterone when compared to the values obtained in the vehicle-treated group, (b) produced signifiant (p< 0.05) reduction in BP in the captopril treated group when compared to the vehicle-treated, (c) did not produce any signficant change in BP in the T. violacea-treated group when compared to the vehicle-treated group and (d) did not produce any signifiant change in HR or body weight in any of the groups. The result obtained in this study suggests that T. violacea reduced BP and HR in the SHR. Secondly, the BP and HR reducing effect of the MLE may involve a) the inhibition of the ACE, b) the inhibition of the beta; adrenoceptors, c) the stimulation of the muscarinic receptors and d) the reduction of the levels of aldosternone in plasma. The results also suggest that the MLE may not act through the angiotensin II receptors or the alpha adrenergic receptors. / South Africa

En France, le syndrome coronaire aigu (SCA) représente environ 100 000 hospitalisations par an. Il est recommandé, en prévention secondaire du SCA, un traitement combinant quatre classes médicamenteuses : bêtabloquants, antiagrégants plaquettaires, statines, et inhibiteurs de l’enzyme de conversion ou antagonistes des récepteurs à l’angiotensine II(combinaison BASI). L’objectif de ce travail était l’étude, en situation réelle de soin et en population générale, de l’utilisation et de l’effectivité de la combinaison thérapeutique recommandée en prévention secondaire du SCA. Nous avons d’abord exploré le potentiel représenté par les bases de données médicoadministratives françaises pour cette évaluation. Nous avons ensuite étudié l’utilisation de la combinaison BASI : 42 % des patients étaient traités par la combinaison BASI en post-SCA et 57 % d’entre eux étaient encore traités à deux ans ; la persistance au traitement était plus faible chez les patients âgés, chez ceux ayant d’autres co-morbidités et chez ceux ayant eu un SCA de nature autre qu’un infarctus du myocarde.Nous avons enfin étudié l’effectivité de la combinaison BASI : la combinaison BASI était la combinaison thérapeutique la plus effective à long terme après un SCA chez les patients avec antécédent d’insuffisance cardiaque ; chez les patients sans antécédent de ce type la combinaison sans bêtabloquants n’était pas associée à une augmentation du risque.Ces résultats permettent de reconsidérer l’intérêt à long terme de l’ensemble de la combinaison BASI en post-SCA chez tous les patients et mettent en avant la nécessité de renforcer les stratégies d’éducation thérapeutique. / Acute coronary syndrome (ACS) causes approximately 100,000 hospitalisations per year in France. In secondary prevention of ACS, guidelines advocate pharmacological treatment combining four drug classes: beta-blockers, antiplatelet agents, statins and angiotensin converting enzyme inhibitors or angiotensin receptor blockers (recommended combination).The aim of this work was to study, in real life and among the general population, the use and the effectiveness of the recommended combination for secondary prevention of ACS.Firstly, we explored the potential represented by the French claims databases in this context. Secondly, we studied the use of the recommended combination: 42% of patients were treated with the recommended combination in post-ACS and 57% of them were still treated two years after; persistence to combination was lower in older patients, in those with other comorbidities and those who had an ACS different of myocardial infarction. Thirdly, we studied the effectiveness of the recommended combination: the recommended combination was the most effective combination therapy at long-term in post-ACS patients with history of heart failure; in patients without such history the combination without betablockers was not associated with an increased risk. These results could help reconsidering the long-term interest of the full recommended combination in all ACS patients and highlight the need to strengthen patient education strategies.

Le pore de transition de perméabilité mitochondriale (PTPm) joue un rôle majeur dans la mort cellulaire et dans la cardioprotection. Notre hypothèse est que le complexe I de la chaîne respiratoire est impliqué dans la régulation de l’ouverture du PTPm. Sur des mitochondries isolées de cœurs des rongeurs, nous avons pu démontrer que le PTPm est désensibilisé par la cyclosporine A, un inhibiteur de la cyclophiline D (CyP-D), et cet effet est largement amplifié en présence de la roténone, un inhibiteur du complexe I. Ces résultats ont été confirmés chez la souris CyP-D déficiente. L’étude de plusieurs types cellulaires a aussi confirmé l’effet de la roténone dans la régulation du PTPm. Ainsi, nous avons pu montrer que le flux d’électrons travers le complexe I est capable de réagir sur un site de régulation du PTPm cardiaque masqué par la CyP-D. De plus, les analogues de l’ubiquinone, élément de la chaîne respiratoire impliqué dans le transfert d’électrons entre les complexes I, II et III, modulent la susceptibilité du PTPm vis-à-vis du Ca2+. Par ailleurs, dans un modèle de cœur isolé du rat, le postconditionnement par le perindoprilate, un inhibiteur de l’enzyme de conversion, diminue la taille de l’infarctus après l’ischémie-reperfusion d’une façon NO-dépendant. L’ensemble de nos résultats ouvre de nouvelles perspectives thérapeutiques dans la cardioprotection et montre l’importance du complexe I et de la CyP-D comme cibles moléculaires incontournables dans la cardioprotection / The mitochondrial permeability transition pore (mPTP) plays an important role in cell death and cardioprotection. Our hypothesis is that the complex I of mitochondrial respiratory chain regulates the opening of mPTP. We showed that the opening of mPTP was inhibited by Cyclosporin A (CsA), a cyclophilin D (CyP-D) inhibitor, in mitochondria isolated from rodent heart, and this effect was largely amplified by rotenone, a complex I inhibitor. These results were confirmed in mitochondria devoid of CyP-D. A study realised in several cell lines also confirmed the effect of rotenone in mPTP regulation. We concluded that the electron flow through the respiratory chain complex I regulate mPTP opening and the regulatory site is masked by CyP-D in cardiac mitochondria. Moreover, two analogues of ubiquinone, mobile carrier of electrons between complex I, II and complex III, modulate the susceptibility of mPTP. In addition, in a model of isolated rat heart, postconditioning with Perindoprilat, an angiotensin converting enzyme inhibitor, protects the heart from ischemia-reperfusion injury in an NO-dependant manner. The findings of the present work put new therapic perspectives in cardioprotection

Na África subsaariana, as serpentes do gênero Bitis são de extrema importância, pois suas vítimas apresentam sintomas como dano local, hemorragia e uma severa hipotensão. Este trabalho identificou moléculas capazes de inibir a atividade da enzima conversora de angiotensina I (ECA) presentes no veneno de quatro serpentes do gênero Bitis. Para isto, as porções de baixa massa molecular desses 4 venenos foram fracionadas em RP-HPLC e as frações com boa inibição sobre a atividade da ECA foram analisadas por espectrometria de massas. Foram identificados 34 oligopeptídeos ricos em prolina (PRO), sendo 8 sintetizados e suas constantes de inibição (Ki) determinadas. Em testes com substratos naturais da ECA, angiotensina I e bradicinina, foi constatada a maior inibição da hidrólise da angiotensina I por quatro PROs. Todos os PROs in vivo reduziram a pressão arterial, e seis deles aumentaram a frequência cardíaca em ratos Wistar. Com isto, conclui-se que existem toxinas no veneno de serpentes do gênero Bitis responsáveis pela hipotensão. / In the sub-saharian Africa, snakes from the Bitis genus are of extreme medical importance, since its victims show symptoms as local tissue damage, hemorrhage and a severe hypotension. This work identified molecules that inhibit the angiotensin I converting enzyme (ACE) in the venom of 4 snakes from the Bitis genus. The low molecular portions of the venom of these snakes were fractionated in RP-HPLC and the fractions that efficiently inhibited the ACE activity were analyzed by mass spectrometry. 34 proline-rich oligopeptides were identified, 8 of them synthesized and had their inhibition constants (Ki) determined. In tests using natural substrates of ACE, angiotensin I and bradykinin, the angiotensin I hydrolysis were better inhibited by four PROs. In vivo tests results showed that all PROs decreased the mean arterial pressure and six of them increased the heart rate. Therefore, we can conclude that there are toxins present in the venom of Bitis capable of cause hypotension.

As doenças cardiovasculares (DCV) são responsáveis pela maioria das mortes ocorridas em todo o mundo. Os riscos para o desenvolvimento destas patologias podem ser amenizados, em parte, por meio de uma dieta rica em alimentos de origem vegetal. Neste sentido, os frutos nativos brasileiros, como os pertencentes à família Myrtaceae, podem contribuir para melhorar a qualidade da alimentação, pois apresentam altos teores de compostos bioativos, entre eles, os fenólicos (CBF). Pouco se sabe sobre os efeitos dos polifenóis destes frutos para redução do risco de desenvolvimento das DCV. Sendo assim, este trabalho buscou avaliar a bioacessibilidade dos CBF presentes em polpas de cambuci e jabuticaba e seus efeitos in vitro sobre mecanismos de ação relacionados às DCV. Para tanto, extratos ricos em polifenóis foram obtidos a partir de extrações em fase sólida (C18 e PA) das polpas de ambos os frutos, submetidas ou não à simulação da digestão gastrointestinal. Estes extratos tiveram seus efeitos inibitórios sobre a atividade da Enzima Conversora de Angiotensina I (ECA) e a agregação plaquetária induzida por adenosina difosfato avaliados in vitro. De acordo com os resultados obtidos, a digestão in vitro foi capaz de liberar os CBF da matriz alimentar. Tal bioacessibilidade parece ter sido importante apenas para a inibição da agregação plaquetária, uma vez que a capacidade inibitória destes compostos sobre a atividade da ECA não melhorou depois da digestão in vitro. Quanto aos resultados obtidos pelos extratos provenientes das colunas PA e C18, observa-se que as maiores concentrações de taninos nestes últimos não foram suficientes para melhorar a capacidade antiagregante, mas foram importantes para aumentar a inibição da atividade da ECA. Comparando-se as respostas apresentadas pelos dois frutos, os CBF presentes no cambuci exibiram, predominantemente, potenciais anti-hipertensivo e antiagregantedo maiores do que os da jabuticaba. Neste contexto, o consumo de cambuci e jabuticaba, bem como a utilização de seus polifenóis purificados, podem ser adjuvantes para a redução dos riscos relacionados ao desenvolvimento das DCV. / The cardiovascular diseases (CVD) are the leading cause of death worldwide. The risk of development of these disorders can be reduced, partially, by a vegetal-based diet. In this way, the Brazilian native fruits from Myrtaceae family may contribute to improve the diet quality, once they have high quantity of bioactive compounds, such as the phenolic (PC). The knowledge about the cardioprotective effects of consuming these fruit polyphenols is limited, so this study aimed to evaluate the bioaccessibility of the cambuci and jaboticaba PC and their in vitro potential on CVD-related mechanisms. First, gastrointestinal digestion simulation of each fruit pulp was done, and then the polyphenols rich extracts were obtained by solid phase extractions, before and after the pulps digestion. The polyphenols rich extracts had their phenolic concentrations determined and were used to evaluate the capacity of PC in inhibit the Angiotensin Converting Enzyme (ACE) activity and the platelet aggregation induced by ADP. The results were expressed as IC50, considering the total phenolic content per milliliter of reaction. According to the results, the in vitro digestion process was able to release the polyphenols from the food matrix. Therefore, the bioaccessibility had no significant effect on ACE activity, but decreased the IC50 values of platelet aggregation. In relation to the extracts from PA and C18 columns, the higher tannin concentration In comparison to the IC50 values presented by PA extracts, the higher concentrations of tannins in the last one were not enough to improve the antiaggregant effect, but were important to increase the inhibition of ACE activity. Cambuci polyphenols presented higher antihypertensive and antiaggregant potentials than the jaboticaba compounds. In this respect, the ingestion of cambuci and jaboticaba and the use of their purified polyphenols can be of particular importance in reducing the risk for the CVD development.

Les maladies coronariennes sont l'une des principales causes de décès dans le monde. Comment les artères coronaires sont modelées et quelles sont les molécules de signalisation qui régissent ce processus, sont des mécanismes mal compris. Dans la première partie de ma thèse, j'ai identifié le modulateur de signalisation Wnt Rspo3 comme un régulateur crucial de la formation de l'artère coronaire dans le cœur en développement. Rspo3 est spécifiquement exprimé autour des branches coronaires à des moments critiques dans leur développement. L'ablation temporelle de Rspo3 conduit à une diminution de la signalisation de β-caténine et à une réduction de la prolifération spécifique des artères. En conséquence, les branches coronariennes sont défectueuses et l'arbre artériel ne se forme pas correctement. Ces résultats identifient un mécanisme par lequel l'expression localisée de RSPO3 induit la prolifération des artères coronaires à leurs branches permettant leur formation. Le traitement des patients qui se remettent d'un infarctus du myocarde (IM) est difficile car les cardiomyocytes ont une capacité très limitée à régénérer le cœur endommagé. La voie de signalisation de l'acide rétinoïque (AR) est essentielle pour le développement cardiaque et joue un rôle protecteur dans les cœurs endommagés. Pour la deuxième partie de ma thèse, j'ai utilisé une nouvelle lignée rapportrice de l’AR et j'ai observé une réponse spécifique des cardiomyocytes. L'ablation de la signalisation de l’AR par délétion génétique des enzymes Raldh1/2/3 entraîne une augmentation de l'apoptose myocytaire à la fin du développement tardif et après l'IM. Le séquençage des ARNs des cardiomyocytes primaires révèle que le traitement à l’AR réprime l'expression de Ace1, indiquant un nouveau lien entre la signalisation AR et le système Rénine Angiotensine dans le contexte de la réparation cardiaque. / Coronary heart disease is one of the leading causes of death worldwide. How coronary arteries are remodeled and the signaling molecules that govern this process are poorly understood. For the first part of my thesis, I have identified the Wnt-signaling modulator Rspo3 as a crucial regulator of coronary artery formation in the developing heart. Rspo3 is specifically expressed around the coronary stems at critical time-points in their development. Temporal ablation of Rspo3 leads to decreased β-catenin signaling and a reduction in arterial-specific proliferation. As a result, the coronary stems are defective and the arterial tree does not form properly. These results identify a mechanism through which localized expression of RSPO3 induces proliferation of the coronary arteries at their stems and permits their formation. Treating patients recovering from myocardial infarction (MI) is difficult since cardiomyocytes have a very limited capacity to proliferate and regenerate the damaged heart. The Retinoic Acid (RA) signaling pathway is essential for cardiac development and plays a protective role in damaged hearts. For the second part of my thesis, I have utilized a novel RA reporter line and I have observed a cardiomyocyte-specific response. Ablation of RA signaling through genetic deletion of the Raldh1/2/3 enzymes leads to increased myocyte apoptosis both during late development and after MI. RNA sequencing analysis of primary cardiomyocytes reveals atRA treatment represses Ace1 expression, providing a novel link between RA signaling and the Renin Angiotensin System in the context of heart repair.